key: cord-0799092-6wi7mmfm
authors: Rizvi, Anam; Patel, Zankesh; Liu, Yan; Satapathy, Sanjaya K.; Sultan, Keith; Trindade, Arvind J.
title: Gastrointestinal sequelae three and six months after hospitalization for Coronavirus Disease 2019
date: 2021-07-01
journal: Clin Gastroenterol Hepatol
DOI: 10.1016/j.cgh.2021.06.046
sha: cc6091615cec28449a5a05f193192afcb099df20
doc_id: 799092
cord_uid: 6wi7mmfm

Gastrointestinal (GI) symptoms are highly prevalent in coronavirus disease 2019 (COVID-19) ranging from 17.6 % to 53 %.1-4 The proposed mechanism for GI symptoms involves SARS-CoV-2 virus binding to the host cell's angiotensin-converting enzyme-2 receptor, commonly found in GI tract epithelial cells.5.

Gastrointestinal (GI) symptoms are highly prevalent in Coronavirus Disease 2019 (COVID-19) ranging from 17.6% to 53% [1] [2] [3] [4] . The proposed mechanism for GI symptoms involves SARS-CoV-2 virus binding to the host cell's angiotensin-converting enzyme 2 (ACE2) receptor, commonly found in gastrointestinal tract epithelial cells 5 .

With an increasing population of patients recovering from acute infection, there is now interest in understanding post-COVID-19 sequelae. Our study aims to report gastrointestinal sequelae 3 and 6 months after hospitalization for COVID-19 infection.

This is a multicenter, retrospective study of hospitalized adult patients (18 years and older) who tested positive for COVID-19 infection from March 1 st , 2020 to January 24 th , 2021 across 12 hospitals comprising the Northwell Health System in New York. Patients were included if 1) tested positive for SARS-CoV-2 nasal swab PCR 2) were hospitalized with GI manifestations on initial presentation 3) had 3 and/or 6 months follow up as an outpatient post-hospitalization or repeat hospitalization. Further description of methods included in supplemental material. 

We report the following important findings from 3 and 6 month follow up regarding GI symptoms and COVID-19 disease:

 GI manifestations of COVID-19 disease are common (18.5% in our cohort).

 Most initial presentations of GI bleeding, gastroenteritis and pancreatitis associated with COVID-19 infection resolve by 3 months follow up.

 Malnutrition is the most persistent GI sequelae without resolution at 3 and 6 months follow up intervals. A significant portion of patients with these complaints may have difficulty gaining weight long term (i.e. a median 14.7 pound weight loss remained for these patients at 6 months follow up).

Our study provides reassurance that most individuals with the onset of GI bleeding or gastroenteritis associated with COVID-19 infection will have resolution of these symptoms. Our study highlights the need to pay particular attention to COVID-19 patients who suffer from malnutrition during their initial hospitalization. Many of these patients may have on-going malnutrition or weight loss despite resolution of COVID-19 infection. Therefore it may be imperative to establish malnutrition screening practices in post-COVID 19 patients who have recovered from acute infection 6, 7 .

The strengths of our study include the largest cohort of patients with follow up data of COVID-19 associated GI symptoms to date, a diverse patient population across multiple hospitals in Long Island, In conclusion, GI symptoms of malnutrition, weight loss, and anorexia may persist for several months after COVID-19 infection and may require further medical attention, while GI bleeding, gastroenteritis, and pancreatitis are likely to resolve after initial presentation. J o u r n a l P r e -p r o o f

Institutional review board approval was obtained for this study. ICD-10 codes for the following gastrointestinal symptoms were used to screen patients for initial GI manifestations: gastrointestinal bleeding (upper GI bleed, lower GI bleed, melena, hematochezia, hematemesis, bright red blood per rectum), gastroenteritis (abdominal pain/diarrhea/nausea/vomiting), malnutrition (including severe, moderate, mild protein calorie malnutrition per nutrition assessments, and anorexia), and pancreatitis. These GI manifestations were selected for the following reasons: gastroenteritis symptoms have been well described as a component of the acute presentation of COVID-19, GI bleeding has been well described in the COVID-19 literature 1,2 , critical and prolonged COVID-19 hospitalization courses may result in malnutrition, and acute pancreatitis has been described as an entity associated with COVID-19 infection 3, 4 . Pancreatitis was diagnosed based on the Atlanta classification. Clinical information was collected from electronic medical records using a standardized data collection sheet. We included malnutrition in the study as we have been anecdotally seeing patients with prior COVID-19 who are unable to have weight regain.

Patient charts were reviewed manually to confirm presence of GI manifestations at admission, GI bleeding and malnutrition during course of initial COVID-19 hospitalization and evaluate symptoms at 3 and 6 months follow up visits. 3 month follow up criteria included outpatient visit or repeat hospitalization 3 months after initial hospitalization date (up to 6 months), and similarly 6 month follow up was considered 6 months after initial hospitalization date. Upon manual chart review the following were excluded: those with anemia not secondary to GI bleeding, pancreatitis secondary to non-viral etiologies, and those patients with multiple gastroenteritis symptoms were consolidated (ie if abdominal pain, nausea, and vomiting all present, patient was counted for this symptom one time in the gastroenteritis category). Our population cohort had a rate of IBS and IBD at 1% and 2% respectively and thus were not excluded from the study. While there are a total number of patients in the study, some patients experienced two or more unique GI manifestations (ie if GI bleeding and malnutrition both occurred in the same patient, this was counted as two distinct GI manifestations however one patient in the study overall).

Resolution of each symptom was determined via chart reviewfor gastroenteritis symptoms it is the resolution of abdominal pain, nausea, vomiting, diarrhea on subsequent follow up, for GI bleeding is the absence of repeat episode of GI bleeding on follow up, for pancreatitis is it absence of recurrence of another acute pancreatitis episode/sequelae of pancreatitis, and for malnutrition based on the ability to have weight regain (the only objective marker that can be abstracted easily).

For those patients with symptoms of malnutrition, anorexia, and weight loss, weight assessments at admission, 3 and 6 months were documented. In addition those with malnutrition were documented as such on initial hospitalization via a nutrition consult by a board certified nutritionist. Descriptive statistical analysis was performed.

J o u r n a l P r e -p r o o f

Endocr Metab Immune Disord Drug Targets, 2021. Online ahead of print

Gastrointestinal bleeding in hospitalized COVID-19 patients: a propensity score matched cohort study

Gastrointestinal Bleeding in Patients With Coronavirus Disease 2019: A Matched Case-Control Study

Risk Factors, and Outcomes of Hospitalized Patients With Coronavirus Disease 2019 Presenting as Acute Pancreatitis

Clinical Outcomes of Acute Pancreatitis in Patients With Coronavirus Disease